SCHEMBL1655911

SCHEMBL1655911

COc1cc(C#N)c(C(=O)c2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.54
MRGPRX4 Q96LA9 5/20 0.52
XDH P47989 2/20 0.50
NPC1 O15118 1/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SMPD1 P17405 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
SRD5A2 P31213 3/20 0.46
SRD5A1 P18405 2/20 0.46
RXRA P19793 1/20 0.46
MAOB P27338 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1658637 0.93 ATM (0.50) ATMMRGPRX4XDHNPC1HPGD
SCHEMBL1656955 0.89 CTSV (0.54) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL12082091 0.88 XDH (0.44) ATMMRGPRX4XDHNPC1HPGD
SCHEMBL1656919 0.88 XDH (0.49) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL1656212 0.87 ALDH1A1 (0.56) ATMMRGPRX4XDHNPC1HPGD
SCHEMBL12082183 0.87 SMPD1 (0.50) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL12082126 0.85 XDH (0.47) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL12082257 0.85 XDH (0.47) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL12082295 0.85 HPGD (0.50) MRGPRX4XDHNPC1HPGDRAB9A
SCHEMBL12082023 0.84 XDH (0.44) MRGPRX4XDHNPC1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305633-B1 Catechol derivative and its use KISSEI PHARMACEUTICAL (JP) 2013-03-20 EP disclosed
US-8258162-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-04 US disclosed
US-20110172208-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-07-14 US disclosed
EP-2305633-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE AND USE OF THE PHARMACEUTICAL COMPOSITION Kissei Pharmaceutical Co., Ltd. (JP) 2011-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172208-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION COMT, CYP3A5, CYP2D6 ATM 4702/4885MRGPRX4 1048/4885XDH 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.